2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5204 Immunophenotype adds prognostic value beyond fusion partner alone in pediatric KMT2A-rearrenged AML: A report from the Children's Oncology Group AAML1031 protocol.

Andrew J. Menssen, Ph.D., HCLD(ABB), Amenech B. Ashango2, Todd A. Alonzo, PhD3, Robert B. Gerbing, Ph.D4, Maria Pardo5, Fan-Chi Hsu, PhD6, Loren L. Lott7, Fangyan Dai8, Denise A. Wells, MD9, Todd Cooper I, DO10, Jessica A. Pollard I, MD11, Katherine Tarlock I, MD12, Soheil Meshinchi, MD, PhD13, Richard Aplenc I, MD, PhD14, Lisa Eidenschink Brodersen, PhD15, Michael Loken, PhD16, Chad A. Hudson, MD, Ph.D17
1 Hematologics. Inc., Seattle, Washington, United States
2 Hematologics. Inc., Seattle, Washington, United States
3 Children’s Oncology Group, Arcadia, California, United States, University of Southern California, Los Angeles, California, United States
4 Children’s Oncology Group, Arcadia, California, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Hematologics. Inc., Seattle, Washington, United States
6 Hematologics. Inc., Seattle, Washington, United States
7 Hematologics. Inc., Seattle, Washington, United States
8 Hematologics. Inc., Seattle, Washington, United States
9 Hematologics. Inc., Seattle, Washington, United States
10 Seattle Children's Hospital, Seattle, Washington, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Seattle Children's Hospital, Seattle, Washington, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
15 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Hematologics. Inc., Seattle, Washington, United States
17 Hematologics. Inc., Seattle, Washington, United States

Introduction: Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with diverse features and variable clinical outcomes. KMT2A-rearranged (KMT2A-r) AML represents a unique subset characterized by multiple fusion partners, various immunophenotypes, and heterogeneous clinical behavior. In this study, we evaluated the distribution of KMT2A-r AML across immunophenotypic clusters in the COG AAML1031 clinical trial and examined associations between phenotype, fusion partners, clinical features, and outcomes.

Methods: Children with de novo AML enrolled in AAML1031 who submitted diagnostic bone marrow specimens were included (n=1034). Antigen expression of AML cells was measured by multidimensional flow cytometry and quantified as previously published. Fourteen antigens plus side scatter were utilized for unsupervised hierarchical clustering and immunophenotypic clusters were identified by blinded manual review. KMT2A rearrangement, clinical characteristics, and outcomes were evaluated across the clusters with the hypothesis that immunophenotypic cluster would provide additional clarity for these patients.

Results: Ten immunophenotypic AML clusters (A-J) (range: 11-321 patients) were identified. Across the cohort, 237 patients (22.9%) had KMT2A rearrangements, with the three most common fusions being KMT2A::MLLT3 (n=90), KMT2A::MLLT10 (n=53), and KMT2A::MLLT4 (n=24). KMT2A-r AML was distributed across almost all clusters (A=9 patients, B=6, C=5, D=13, E=10, G=58, H=106, I=9, and J=21) but by frequency was enriched in clusters B (55% of cluster), D (68%), H (73%), I (81.8%), and J (51%). While a high number of KMT2A-r patients were found in cluster G the frequency within that cluster (22%) was not notably elevated due to the large relative size of the cluster (n=260). An analysis of specific KMT2A fusions lacked associations with specific clusters, indicating that fusion partner does not appear to be a significant driver of immunophenotype.

KMT2A enriched clusters exhibited distinct characteristics, representing the heterogeneity of KMT2A-r AML. Cluster B was characterized by CD34, CD64, and increased CD123 expression without CD117 and contained younger patients (median age: 2.0 years). Clusters D and J demonstrated monocytic expression with or without (respectively) CD34, with J also exhibiting the highest diagnostic WBC (36.8 ×10³/µL). Clusters H and I also exhibited monocytic differentiation without CD34 expression but were separated by the absence (H) or presence (I) of CD56 and CD117 expression. Clusters D, H, and J demonstrated low rates of MRD post induction 1 (11%, 6%, and 15%, respectively), while B and I were comparable to the entire study (27% and 20%, respectively).

Clinical outcomes varied across immunophenotypic subsets of KMT2A-r AML. Poor outcomes were observed in clusters B (5-year EFS and CIR: 11% and 85%), D (26% and 62%), and I (27% and 60%). Although high-risk KMT2A-r patients (as defined for AAML1831: KMT2A with: AFF1, MLLT10, ABI1, MLLT1, or AFDN) were enriched in clusters G (19/103) and H (7/15) these clusters did not demonstrate particularly poor outcomes in comparison to others, with 5-year EFS/CIR of 51%/36% and 38%/56%, respectively. A comparison of outcomes between clusters for the two most frequent fusions revealed significant differences. For MLLT3 fusions, patients in cluster J did the worst (albeit in small sample size) followed by G and H (DFS: 0%, 27%, 37%, p=0.03). For patients with MLLT10 fusions cluster B had the poorest outcomes followed by H, D, and E (DFS: 0%, 15%, 50%, and 67%, p=0.005).

Conclusion: Immunophenotype provides additional information beyond KMT2A fusion partner, identifying additional subsets of KMT2A-r AML. While fusion partner does not appear to drive immunophenotype, specific immunophenotypic subsets of KMT2A-r AML are observed, raising questions regarding the underlying cause. Comparison of outcomes revealed differences, including within the same fusion. The poor outcomes for patients in clusters B and D, both of which demonstrated CD34 expression, suggest that CD34 expression could be considered in the prognosis of these patients. Cluster B in particular demonstrates a distinct immunophenotype and had especially poor outcomes despite not being enriched in high-risk KMT2A fusions. Together, data suggests that incorporating immunophenotypic classification alongside fusion partner status may improve prognostic assessment in KMT2A-r AML.
Andrew J. Menssen, Ph.D., HCLD(ABB): Hematologics Inc - Current Employment